Vounckx, Manon
Tijtgat, Jens
Stevens, Latoya
Dirven, Iris
Ilsen, Bart
Vandenbroucke, Frederik
Raeymaeckers, Steven
Vekens, Karolien
Forsyth, Ramses
Geeraerts, Xenia
Van Riet, Ivan
Schwarze, Julia Katharina
Tuyaerts, Sandra
Decoster, Lore
De Ridder, Mark
Dufait, Ines
Neyns, Bart
Clinical trials referenced in this document:
Documents that mention this clinical trial
694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)<sup>+</sup>/CD141(BDCA-3)<sup>+</sup>myeloid dendritic cells in solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0694
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors
https://doi.org/10.1007/s00262-024-03751-0
Article History
Received: 15 March 2024
Accepted: 29 May 2024
First Online: 2 July 2024
Declarations
:
: Conflict of interest: Manon Vounckx: Research funding from Kom op tegen Kanker Jens Tijtgat: Since January 2024 Disease Area Specialist (Medical Lead) Thoracic Oncology at Bristol Myers Squibb Iris Dirven: Research funding: Kom op tegen Kanker; Travel, Accomodations, Expenses: AstraZeneca, Pierre Fabre Julia Katarina Schwarze: JKS reports non-financial support from MSD and Amgen; personal fees from Novartis.Lore Decoster: payments to institution for advisory boards, consultancy, lectures, travel from Astra Zeneca, Roche, MSD, BMS, Servier, Lilly Bart Neyns: Personal financial compensation for public speaking, consultancy, and participation in advisory board meetings from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis. My institution (UZ Brussel) received research funding related to research projects conducted by my team from Pfizer, Novartis, Roche, and Merck-Serono